Richard E. Kuntz, M.D., M.Sc., is senior vice president, chief medical and scientific officer of Medtronic, Inc., and serves as a member of the company’s executive committee. In this role, Kuntz oversees the company’s medical affairs, health policy and reimbursement, clinical research activities, and corporate technology.
Kuntz joined Medtronic in October 2005 as senior vice president and president of Medtronic Neuromodulation, which encompasses the company’s products and therapies for the treatment of chronic pain, movement disorders, spasticity, overactive bladder and urinary retention, benign prostatic hyperplasia, and gastroparesis. In this role, he was responsible for the research, development, operations, and product sales and marketing for each of these therapeutic areas worldwide.
Kuntz brings to Medtronic a broad background and expertise in many different areas of healthcare. Prior to his tenure at Medtronic, he was the founder and chief scientific officer of the Harvard Clinical Research Institute, a university-based contract research organization that coordinates National Institutes of Health and industry clinical trials with the U.S. Food and Drug Administration. Kuntz has directed over 100 multicenter clinical trials and has authored more than 250 original publications. His major interests are traditional and alternative clinical trial design and biostatistics.
Kuntz also served as associate professor of medicine at Harvard Medical School, chief of the Division of Clinical Biometrics, and an interventional cardiologist in the division of cardiovascular diseases at the Brigham and Women’s Hospital in Boston, Massachusetts. Kuntz has served as a member of the Board of Governors of the Patient Centered Outcomes Research Institute since it was established in 2010 as part of the Affordable Care Act.
Kuntz graduated from Miami University and earned his M.D. in surgery from Case Western Reserve University School of Medicine. He completed his residency and chief residency in internal medicine at the University of Texas Southwestern Medical School, and then completed fellowships in cardiovascular diseases and interventional cardiology at the Beth Israel Deaconess Medical Center and Harvard Medical School in Boston, Massachusetts. Kuntz received his M.Sc. of science in biostatistics from the Harvard School of Public Health.